Inimmune Corporation, a US-based clinical-stage biotechnology company, announced on Tuesday that it has signed a research collaboration with Boston Children's Hospital (BCH).
The research collaboration is aimed at developing novel and innovative small molecule vaccine adjuvants. An adjuvant is added to some vaccines to enhance the immune response, thereby creating a stronger and longer-lasting immunity against infections than the vaccine alone.
The Precision Vaccines Program (PVP) at Boston Children's Hospital was awarded a Vaccine Adjuvant Development Program contract (75N93023C00040) from the National Institutes of Health (NIH)/National Institute of Allergy and Infectious Diseases (NIAID) that can extend up to five years and USD9m to develop a small molecule TLR7/8 agonist adjuvant that will enhance the effectiveness of flu vaccines.
Ofer Levy, MD, PhD, director of the PVP, said: "The Precision Vaccines Program is dedicated to pioneering the next generation of vaccines tailored to safeguard the most vulnerable among us. We are building a global network to revolutionise vaccine development, and we are excited to collaborate with Inimmune to enhance adjuvants."
EURneffy approved in EU for needle-free anaphylaxis treatment
Crossject secures EUR6.9m French government grant to advance ZENEO Epinephrine
Celltrion USA submits CT-P39 Biologics License Application to FDA
Ionis Pharmaceuticals names new executive vice president, chief global product strategy officer
Allergy Therapeutics reports positive G306 Phase III trial results for Grass MATA MPL
NeoImmuneTech's NT-I7 receives US FDA Orphan Drug Designation
Allergy Therapeutics reports positive interim results for G306 Phase III trial